We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects (THYMON-10001)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01144026
First Posted: June 15, 2010
Last Update Posted: January 18, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Thymon, LLC
  Purpose
This protocol represents the second in human study of TUTI-16, and is being conducted to continue to gather safety and human immunogenicity (anti-HIV-1 Tat titers) data of subcutaneously administered TUTI-16.

Condition Intervention Phase
HIV Infections Biological: TUTI-16 (0.2mg) Biological: TUTI-16 (1.0 mg) Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/IIA Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects

Resource links provided by NLM:


Further study details as provided by Thymon, LLC:

Primary Outcome Measures:
  • Anti-Tat Antibody Titer [ Time Frame: 5 weeks ]
    ELISA based chemiluminescent assay to determine the anti-Tat antibody response


Enrollment: 15
Study Start Date: September 2010
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TUTI-16 (0.2mg)
Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
Biological: TUTI-16 (0.2mg)
Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
Experimental: TUTI-16 (1.0 mg)
Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
Biological: TUTI-16 (1.0 mg)
Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.

Detailed Description:

HIV-1 Tat protein, a virally encoded toxin, is secreted by HIV-1 infected cells and acts on uninfected cells, rendering them permissive for HIV-1 replication. HIV-1 Tat enhances chronic viral replication and induces immune suppression. Antibodies to Tat inhibit this Tat-mediated transcellular activation in vitro and minimize chronic plasma viremia. HIV-1 Tat activities can be blocked in vitro and in vivo by anti-Tat antibodies.

The Thymon Universal Tat Immunogen (TUTI-16) is a fully synthetic, self-adjuvanting lipopeptide vaccine that is water soluble and administered by subcutaneous injection. In preclinical studies, a priming dose and a three week boost in rats induced a high titer antibody response to the eight known distinct epitope variants of HIV-1 Tat protein. These antibodies block the function of the HIV-1 Tat protein (toxin), which is essential to the maintenance of chronic HIV-1 viremia. Therefore, TUTI-16 has potential as a therapeutic vaccine for HIV-1 in humans.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males and Females
  • Age ≥18 and ≤50 years at Screening
  • HIV negative healthy subjects or HIV-1 seropositive subjects on effective ART for >2 months (undetectable HIV plasma viremia), viral set point before ART >3,000
  • CD4+ T-cell count ≥ 500/mm3.

Exclusion Criteria:

  • Pregnant/nursing females
  • Positive for HBV or HCV
  • Acute Herpetic event
  • Any clinically significant out-of range laboratory value
  • Routine or PRN consumption of immune suppressive medications that the subject is unable or unwilling to discontinue during the study
  • Participation in another investigational drug/vaccine study within 30 days preceding the first injection of investigational agent in this study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01144026


Locations
United States, New York
Clinilabs
New York, New York, United States, 10019
Sponsors and Collaborators
Thymon, LLC
Investigators
Principal Investigator: Mardik Donikyan, MD Clinilabs, Inc.
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Thymon, LLC
ClinicalTrials.gov Identifier: NCT01144026     History of Changes
Other Study ID Numbers: THYMON-10001
First Submitted: June 12, 2010
First Posted: June 15, 2010
Results First Submitted: December 7, 2012
Results First Posted: January 15, 2013
Last Update Posted: January 18, 2013
Last Verified: January 2013

Keywords provided by Thymon, LLC:
HIV
vaccine
lipopeptide
Tat
TUTI-16
THYMON

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases